MGAT2 inhibitors (AstraZeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMGAT2 inhibitors (AstraZeneca)
Drug Alias Namemonoacylglycerol acyltransferase 2 inhibitors (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action2-acylglycerol O-acyltransferase 2 inhibitors
Targets2-acylglycerol O-acyltransferase 2
Therapy Area/IndicationsObesityMetabolic SyndromeDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Ab
Active IndicationsN/A
Inactive IndicationsObesityMetabolic SyndromeDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A